Member Info for gtc1507

Window of opportunity here - next RNS are only going to bring good news and we should be moving up.

Anyone submitted questions in advance of presentation?

Lol don’t be clueso care to elaborate 😂

😂

My buy showing at 11:54 as sells

Interesting at 03:12 in the interview he says that they’re gaining traction in vet medicine “as we speak”. Wonder is there some news in that space to come shortly

Totally, if you think forward the interim results RNS is already going to be saying that H1 revenues are up over 50% on the previous year. We’re moving forward and upwards and the market is just going to take time to wake up. They just didn’t communicate well in the trading update.

Chris, you said this, what grant are you referring to?

RE: Moving up!2 May 2024 14:10

Has to really, imagine when that grant lands

Looks like moving up again..slowly but surely

Wonder will we see news in between!

16 May 11am

Good as I’ve been hounding them too 😂

Part of their fundraising strategy was to boost presence in North American market as well as diagnostic and veterinary according to this. Just the out working of that I suspect

https://www.dlapiper.com/en-us/news/2024/03/dla-piper-advises-leading-biotechnology-business

It says that she started in April 2024 on contract as USA Business Development manager on her job list so they’ve clearly appointed that company or hired her directly to undertake BD activities specifically in the USA

She’s got 16000 followers on LinkedIn so could be a great connected hire who knows!

Says her job title is US business development manager

Agree, there was nothing new in terms of performance in this. The revenues were in line with broker predictions and market expectations. Key new positive info in here for me is:

Order book already beating last years revenues.

Additional revenues from master services agreement with global diagnostics company

Clients requesting multiple contracts and projects at a time.

It’s looking more optimistic for 2024/25 although not without challenges in cash.

What’s your take on this morning? And are you still expecting additional news?

I agreed with comments, we’re all here to help each other rather than be deconstructive. The way I see it there a challenges and big positives:

Positives:

- strong order book versus last year

- recruiting staff to key commercialisation roles

- partnership with global diagnostics company which is generating recurring orders already

- evidence of diversification from previous strategy

- world first technology being validated by worlds most prestigious cancer centre which had £7bn funding from US government last year.

- new class leading technologies, optimal, optiphage, AIMLAB, getting traction in market shortly after development

- other pipeline opportunities in development include Fusion being part of the future medicines institute being developed to strengthen r&d collaboration as part of Northern Ireland life sciences cluster. Hopefully word soon on that being funded.

- royalty and milestone entitlement in a range of projects that could generate future revenue.

- challenges

- cash runway less than a year and dependent on cash neutrality

- interest rate environment might slow biotech and VC recovery that was anticipated

- need to recruit staff to commercialise orders could slow recovery

- lack of corporate and investor comms strategy will probably keep share price depressed to a greater extent unless significant news comes

Market hasn’t dropped the price either as they can read the RNS properly Micho….

Micho you’re a doomslayer, this is in line with market expectations and already priced in 🙈 for long term view loooking at the pipeline of opportunities